VRDN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

20.880

Open

19.220

VWAP

20.17

Vol

3.48M

Mkt Cap

2.26B

Low

19.170

Amount

70.15M

EV/EBITDA(TTM)

Total Shares

110.43M

1.55B

EV/OCF(TTM)

P/S(TTM)

24.10

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Events Timeline

(ET)

2026-06-26

18:30:00

Viridian Therapeutics Receives FDA Approval for Lumvoa to Treat Thyroid Eye Disease

2026-05-07 (ET)

2026-05-07

06:20:00

Deal Size Increased to $125M in Common Stock

News

5.0

06-30Yahoo Finance

Viridian's Lumvoa Therapy for Thyroid Eye Disease Set to Launch

4.5

06-29NASDAQ.COM

U.S. Stocks Close Higher, Led by Technology Gains

4.5

06-29NASDAQ.COM

US Stocks Rise, Led by Technology Sector Gains

4.5

06-29NASDAQ.COM

US Stocks Rise, Led by Technology Sector Gains

8.5

06-29Newsfilter

Universe Pharmaceuticals Acquires Best Praise International

9.0

06-29Newsfilter

FDA Approves Viridian's Lumvoa for Thyroid Eye Disease

17 Analyst Rating

Wall Street analysts forecast VRDN stock price to rise

17 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.20

Averages

41.71

High

61.00

Current: 0.000

Low

14.20

Averages

41.71

High

61.00

Goldman Sachs

Buy

maintain

$35 -> $39

AI Analysis

2026-06-30

Reason

Goldman Sachs

Price Target

$35 -> $39

AI Analysis

2026-06-30

maintain

Buy

Reason

Goldman Sachs raised the firm's price target on Viridian Therapeutics to $39 from $35 and keeps a Buy rating on the shares. Viridian highlighted on its FDA approval call that Lumvoa in thyroid eye disease offers a differentiated profile versus Tepezza, including more convenient dosing, faster onset of proptosis improvement, and encouraging chronic efficacy data, supporting a constructive commercial outlook as the company positions the drug for launch, the analyst tells investors in a research note.

Truist

Buy

maintain

$35 -> $38

2026-06-30

Reason

Truist

Price Target

$35 -> $38

2026-06-30

maintain

Buy

Reason

Truist raised the firm's price target on Viridian Therapeutics to $38 from $35 and keeps a Buy rating on the shares. Viridian highlighted on its Lumvoa approval call a differentiated thyroid eye disease label with more convenient dosing versus Tepezza, pricing at parity, and a commercial strategy targeting a rapid ramp in a large under-penetrated market with meaningful revenue expected by 2027 and additional franchise expansion via a subcutaneous program BLA planned for 1Q27, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VRDN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Viridian Therapeutics Inc (VRDN.O) is 1.01, compared to its 5-year average forward P/E of -4.48. For a more detailed relative valuation and DCF analysis to assess Viridian Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.48

Current PE

1.01

Overvalued PE

-2.67

Undervalued PE

-6.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.83

Current EV/EBITDA

-0.01

Overvalued EV/EBITDA

-1.95

Undervalued EV/EBITDA

-5.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2435.31

Current PS

9.25

Overvalued PS

5027.48

Undervalued PS

-156.86

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks with low shares available to short

Intellectia · 43 candidates

Region: USRelative Vol: >= 1.50Short Ratio: LessThan10PctList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

CMCSA

Comcast Corp

86.52B

UPC

Universe Pharmaceuticals Inc

1.67M

Dynatrace, Inc

12.89B

VRDN

Viridian Therapeutics Inc

2.07B

IFRX

InflaRx NV

282.80M

BGC

Bgc Group Inc

5.49B

give me best stocks to night trade tonight

Intellectia · 84 candidates

Market Cap: >= 500.00MVolume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20Is Optionable: TrueMonthly Average Dollar Volume: >= 300,000News Driver: Positive

Ticker

Name

Market Cap$

EVER

EverQuote Inc

842.59M

STRL

Sterling Infrastructure Inc

24.73B

DOCN

DigitalOcean Holdings Inc

15.94B

VRDN

Viridian Therapeutics Inc

1.93B

BLDP

Ballard Power Systems Inc

1.31B

IART

Integra Lifesciences Holdings Corp

1.03B

surging stocks between 10 to $20

Intellectia · 547 candidates

Price: $10.00 - $20.00Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

FSEA

First Seacoast Bancorp Inc

78.21M

VRDN

Viridian Therapeutics Inc

1.93B

BDSX

Biodesix Inc

151.02M

AIOS

AIOS Tech Inc

63.69M

ONEG

OneConstruction Group Ltd

175.36M

IART

Integra Lifesciences Holdings Corp

1.03B

what to buy High risk

Intellectia · 12 candidates

Market Cap Category: small, midRsi Category: moderateRelative Vol: >= 1.80Beta: HighRiskMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00News Driver: Positive

Ticker

Name

Market Cap$

CIFR

Cipher Digital Inc

9.04B

VRDN

Viridian Therapeutics Inc

1.93B

TDC

Teradata Corp

2.84B

YOU

Clear Secure Inc

7.84B

AVTX

Avalo Therapeutics Inc

434.38M

AZTA

Azenta Inc

1.13B

day trading where do i go

Intellectia · 429 candidates

Price: $2.00 - $100.00Price Change Pct: >= $0.00Relative Vol: >= 1.50Beta: HighRiskMoving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

CLRB

Cellectar Biosciences Inc

12.00M

BLZE

Backblaze Inc

278.47M

AURA

Aura Biosciences Inc

536.07M

CYTK

Cytokinetics Inc

8.21B

VRDN

Viridian Therapeutics Inc

1.45B

EVER

EverQuote Inc

516.80M

which bio stocks is declining

Intellectia · 12 candidates

Market Cap: >= 1000.00MSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchVolume: >= 500,000Price Change Pct: <= $-2.00Moving Average Relationship: PriceBelowMA20

Ticker

Name

Market Cap$

TEM

Tempus AI Inc

7.70B

IBRX

Immunitybio Inc

7.52B

PTGX

Protagonist Therapeutics Inc

6.31B

ADPT

Adaptive Biotechnologies Corp

1.97B

TYRA

Tyra Biosciences Inc

1.90B

GRAL

Grail Inc

1.87B

daytrading

Intellectia · 640 candidates

Market Cap: >= 500.00MPrice Change Pct: $-50.00 - $-2.00Relative Vol: >= 1.50Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

VRDN

Viridian Therapeutics Inc

2.80B

ALMS

Alumis Inc

3.15B

SATL

Satellogic Inc

848.34M

LASR

nLIGHT Inc

3.59B

SYY

Sysco Corp

39.18B

USAS

Americas Gold and Silver Corporation

1.78B

stocks that are prime for day trading.

Intellectia · 1075 candidates

Price: $1.00 - $150.00Price Change Pct: $-50.00 - $-0.50Monthly Average Dollar Volume: >= 100,000

Ticker

Name

Market Cap$

FBLG

Fibrobiologics Inc

13.40M

VRDN

Viridian Therapeutics Inc

2.80B

KSCP

Knightscope Inc

71.51M

ORGN

Origin Materials Inc

19.85M

FCHL

Fitness Champs Holdings Ltd

2.15M

ONCO

Onconetix Inc

1.35M

most bullish ticker next 6 months

Intellectia · 10 candidates

Analyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 20.0%Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200One Month Predict Return: >= 8.0%

Ticker

Name

Market Cap$

SYRE

Spyre Therapeutics Inc

2.93B

GERN

Geron Corp

1.23B

AVNW

Aviat Networks Inc

314.56M

OWLT

Owlet Inc

309.45M

VRDN

Viridian Therapeutics Inc

2.68B

UNCY

Unicycive Therapeutics Inc

139.91M

Whales Holding VRDN

Fairmount Funds Management LLC

Paradigm Biocapital Advisors LP

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Bellevue Asset Management AG

Avoro Capital Advisors LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Viridian Therapeutics Inc (VRDN) stock price today?

The current price of VRDN is 20.47 USD — it has increased 7.79

What is Viridian Therapeutics Inc (VRDN)'s business?

What is the price predicton of VRDN Stock?

Wall Street analysts forecast VRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRDN is41.71 USD with a low forecast of 14.20 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.